Orna Acquires ReNAgade, Bringing Their Shared RNA Interests Under One Roof

Start-Ups Have Raised More Than $700m Already

Orna emerged in 2021 with its circular RNA platform and ReNAgade launched in 2023 to deliver RNA to new tissues, both backed by MPM BioImpact, but they have been partners for years.

Cloud computing concept. Futuristic business network concept. Hi-tech cloud connection technology background. — Orna already uses ReNAgade's technology to deliver its circular RNA • Source: Shutterstock

Two RNA technology specialists created by venture capital investor MPM BioImpact and launched with large amounts of money to pursue their ambitious ideas will bring their shared economic interests under one roof. Orna Therapeutics, Inc. will acquire ReNAgade Therapeutics, just one year after the latter firm emerged with $300m in series A cash, the companies announced on 23 May.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Roche US Exports To Exceed Imports After New $50bn Investment

22 Apr 2025

• By Andrew McConaghie

A brand new R&D center in Massachusetts and a giant manufacturing site for its future obesity drugs are among the key investments in the US.

Korea State R&D Fund Seeks Continuity To Enable Seamless Support

22 Apr 2025

• By Jung Won Shin

The CEO of a South Korean state-run drug R&D support fund urges the renewal of the initiative as it increasingly focuses on new modalities and novel targets.

Roivant Tightens Leadership Grip On Immunovant, Narrows Near-Term IMVT-1402 Focus

21 Apr 2025

• By Mandy Jackson

Roivant president Eric Venker was named CEO of Immunovant to guarantee execution of the development plan for IMVT-1402 in six indications, now including Sjögren’s disease and cutaneous lupus erythematosus.